Phaseline

Companies › VLP Therapeutics

VLP Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VRP-encapsulated saRNA encoding IL-12 (VLPONC-01)
Viral replicon particle (saRNA) expressing IL-12
IL12Phase 1Head and Neck Cancers- Squamous CellDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06736379VRP-encapsulated saRNA encoding IL-12 (VLPONC-01)Phase 1Head and Neck Cancers- Squamous CellOncologyDec 2027

Targets

IL12 (1)

Companies with the same targets

Strand Therapeutics Geneos Therapeutics Suzhou Abogen Biosciences Imunon Sonnet BioTherapeutics Kangabio AUSTRALIA enGene Inovio Pharmaceuticals Trogenix

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.